skip to main content

Chemotherapy Toxicity — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardOncological EmergenciesChemotherapy ToxicitySCE Medical Oncology

A chemotherapy-naive patient is starting cisplatin 75 mg/m². Which prophylactic regimen best covers acute and delayed emesis under current MASCC/ESMO guidance?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: APalonosetron, an NK1 antagonist, dexamethasone and olanzapine

Cisplatin is highly emetogenic. Current MASCC/ESMO guidance recommends four-drug prophylaxis: a 5-HT3 antagonist, NK1 antagonist, dexamethasone and olanzapine. The previous three-drug formulation omitted olanzapine and was no longer current.

Reference: 2023 MASCC and ESMO consensus recommendations for highly emetogenic chemotherapy (Published December 2023): https://pmc.ncbi.nlm.nih.gov/articles/PMC10739516/